# LHX4

## Overview
LHX4 is a gene that encodes the LIM homeobox 4 protein, a transcription factor belonging to the LIM homeodomain family. This protein is characterized by the presence of two LIM domains and a homeodomain, which are essential for its role in DNA binding and protein-protein interactions. LIM homeobox 4 is crucial for the development and function of the pituitary gland and the nervous system, where it regulates the expression of genes involved in pituitary hormone production and neural differentiation (Pfaeffle2008Three; Tajima2013Molecular). Mutations in the LHX4 gene can lead to combined pituitary hormone deficiency (CPHD) and have been implicated in oncogenic processes, such as colorectal cancer, through interactions with signaling pathways like Wnt/β-catenin (Cha2014Oncogenicity; Hemwong2020A). The protein's ability to form complexes with other transcription factors, such as PIT1, underscores its significance in transcriptional regulation and developmental processes (Pfaeffle2008Three).

## Structure
The LHX4 protein is a LIM-homeodomain transcription factor essential for pituitary gland and nervous system development. It comprises two LIM domains and a homeodomain, which are critical for its function in DNA binding and protein-protein interactions (Pfaeffle2008Three). The LIM domains are zinc-binding motifs that contribute to the protein's tertiary structure, facilitating interactions with other proteins (Meier1999Characterization). The homeodomain is involved in DNA binding and is structured as a helix-turn-helix motif, which is crucial for gene regulation (Pfaeffle2008Three).

Mutations in the LHX4 gene can lead to structural changes that affect its function. For instance, the L190R mutation in the homeodomain disrupts the helix-turn-helix structure, impairing DNA binding and gene activation (Pfaeffle2008Three). The A210P mutation also affects the homeodomain, altering protein conformation and reducing DNA binding efficiency (Pfaeffle2008Three). These mutations highlight the importance of the homeodomain's structural integrity for LHX4's role in transcriptional regulation.

Post-translational modifications, such as phosphorylation, may influence LHX4's activity and stability, although specific modifications are not detailed in the provided context. The protein's ability to form complexes with other transcription factors, such as PIT1, is essential for its function in activating pituitary hormone genes (Pfaeffle2008Three).

## Function
The LHX4 gene encodes a transcription factor that is crucial for the development and function of the pituitary gland. It is part of the LIM homeodomain family and contains two LIM domains and a DNA-binding homeodomain, which allow it to regulate gene expression by binding to specific DNA sequences (Tajima2013Molecular). LHX4 is expressed in the developing neural tube, hindbrain, Rathke's pouch, and pituitary gland, playing a significant role in the differentiation of pituitary-specific cell lineages (Fang2016Genetics; Tajima2013Molecular).

In healthy human cells, LHX4 functions as a transcriptional regulator, influencing the expression of genes such as prolactin, TSHβ, FSHβ, and the PIT1 transcription factor, which are essential for pituitary hormone production (Gregory2015Novel). It is active in the nucleus, where it binds to DNA and activates promoters of other transcription factors, such as POU1F1, crucial for pituitary development and hormone production (Takagi2012Gradual; Tajima2013Molecular).

Mutations in LHX4 can lead to combined pituitary hormone deficiency (CPHD), characterized by deficiencies in growth hormone, thyroid-stimulating hormone, and adrenocorticotropic hormone, among others (Tajima2013Molecular). These mutations can impair LHX4's ability to bind DNA and activate gene expression, leading to developmental and functional abnormalities in the pituitary gland (Rochette2015Identifying).

## Clinical Significance
Mutations and alterations in the LHX4 gene are associated with several clinical conditions. In colorectal cancer (CRC), LHX4 is significantly upregulated, promoting cancer cell proliferation through the activation of the Wnt/β-catenin/TCF signaling pathway. This upregulation leads to increased β-catenin levels and the expression of target genes such as c-Myc and DKK1, contributing to oncogenic processes in CRC (Cha2014Oncogenicity).

In the context of pituitary development, mutations in LHX4 can lead to combined pituitary hormone deficiency (CPHD). These mutations can result in structural defects in the pituitary gland and deficiencies in anterior pituitary hormones. For instance, a novel missense mutation (P366T) in LHX4 has been linked to severe CPHD, characterized by symptoms such as hypoglycemia and central hypothyroidism (TAJIMA2007A). Other mutations, such as p.R122W, have been associated with CPHD and affect the transcriptional activity of LHX4, impacting hormone production (Hemwong2020A).

These findings underscore the critical role of LHX4 in both oncogenic processes and pituitary hormone regulation, with mutations leading to significant clinical manifestations.

## Interactions
LHX4 is known to participate in several protein-protein interactions that are crucial for its function as a transcription factor. In colorectal cancer, LHX4 interacts with β-catenin, a key component of the Wnt/β-catenin signaling pathway. This interaction is facilitated by a conserved domain within LHX4, and a specific nine amino acid motif is essential for binding β-catenin. Mutations or deletions in this motif can disrupt the interaction, reducing LHX4's ability to activate target gene promoters and diminishing its tumor-promoting function (Cha2014Oncogenicity). LHX4 also facilitates the binding of TCF4 to β-catenin, forming a stable LHX4/TCF4/β-catenin complex that enhances the transcriptional activity of Wnt/β-catenin target genes (Cha2014Oncogenicity).

In the context of congenital hypopituitarism, LHX4 interacts with proteins such as Ldb1 and PIT1. The LHX4(p.T126M) mutation, located in a highly conserved region of the LIM2 domain, may disrupt interactions with these proteins, potentially affecting protein stability and interactions (Gregory2015Novel). These interactions are critical for the transcriptional regulation of genes involved in pituitary gland development and function (Gregory2015Novel).


## References


[1. (Gregory2015Novel) L. C. Gregory, K. N. Humayun, J. P. G. Turton, M. J. McCabe, S. J. Rhodes, and M. T. Dattani. Novel lethal form of congenital hypopituitarism associated with the first recessivelhx4mutation. The Journal of Clinical Endocrinology &amp; Metabolism, 100(6):2158–2164, June 2015. URL: http://dx.doi.org/10.1210/jc.2014-4484, doi:10.1210/jc.2014-4484. This article has 26 citations.](https://doi.org/10.1210/jc.2014-4484)

[2. (Takagi2012Gradual) Masaki Takagi, Tomohiro Ishii, Mikako Inokuchi, Naoko Amano, Satoshi Narumi, Yumi Asakura, Koji Muroya, Yukihiro Hasegawa, Masanori Adachi, and Tomonobu Hasegawa. Gradual loss of acth due to a novel mutation in lhx4: comprehensive mutation screening in japanese patients with congenital hypopituitarism. PLoS ONE, 7(9):e46008, September 2012. URL: http://dx.doi.org/10.1371/journal.pone.0046008, doi:10.1371/journal.pone.0046008. This article has 19 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0046008)

[3. (Cha2014Oncogenicity) Nier Cha, Wei Liu, Na Yang, Shengzhi Xie, Yanwei Gao, Xia Chen, Xiaoli Wang, and Jun Ren. Oncogenicity of lhx4 in colorectal cancer through wnt/β-catenin/tcf4 cascade. Tumor Biology, 35(10):10319–10324, July 2014. URL: http://dx.doi.org/10.1007/s13277-014-2210-8, doi:10.1007/s13277-014-2210-8. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s13277-014-2210-8)

[4. (Fang2016Genetics) Qing Fang, Akima S. George, Michelle L. Brinkmeier, Amanda H. Mortensen, Peter Gergics, Leonard Y. M. Cheung, Alexandre Z. Daly, Adnan Ajmal, María Ines Pérez Millán, A. Bilge Ozel, Jacob O. Kitzman, Ryan E. Mills, Jun Z. Li, and Sally A. Camper. Genetics of combined pituitary hormone deficiency: roadmap into the genome era. Endocrine Reviews, 37(6):636–675, November 2016. URL: http://dx.doi.org/10.1210/er.2016-1101, doi:10.1210/er.2016-1101. This article has 149 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1210/er.2016-1101)

[5. (Rochette2015Identifying) Claire Rochette, Nicolas Jullien, Alexandru Saveanu, Emmanuelle Caldagues, Ignacio Bergada, Debora Braslavsky, Marija Pfeifer, Rachel Reynaud, Jean-Paul Herman, Anne Barlier, Thierry Brue, Alain Enjalbert, and Frederic Castinetti. Identifying the deleterious effect of rare lhx4 allelic variants, a challenging issue. PLOS ONE, 10(5):e0126648, May 2015. URL: http://dx.doi.org/10.1371/journal.pone.0126648, doi:10.1371/journal.pone.0126648. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0126648)

[6. (Tajima2013Molecular) Toshihiro Tajima, Katsura Ishizu, and Akie Nakamura. Molecular and clinical findings in patients with &lt;i&gt;lhx4&lt;/i&gt; and &lt;i&gt;otx2&lt;/i&gt; mutations. Clinical Pediatric Endocrinology, 22(2):15–23, 2013. URL: http://dx.doi.org/10.1297/cpe.22.15, doi:10.1297/cpe.22.15. This article has 25 citations and is from a peer-reviewed journal.](https://doi.org/10.1297/cpe.22.15)

[7. (TAJIMA2007A) Toshihiro TAJIMA, Tsukasa HATTORI, Takeo NAKAJIMA, Koji OKUHARA, Junko TSUBAKI, and Kenji FUJIEDA. A novel missense mutation (p366t) of the lhx4 gene causes severe combined pituitary hormone deficiency with pituitary hypoplasia, ectopic posterior lobe and a poorly developed sella turcica. Endocrine Journal, 54(4):637–641, 2007. URL: http://dx.doi.org/10.1507/endocrj.k06-200, doi:10.1507/endocrj.k06-200. This article has 45 citations and is from a peer-reviewed journal.](https://doi.org/10.1507/endocrj.k06-200)

[8. (Pfaeffle2008Three) Roland W. Pfaeffle, Chad S. Hunter, Jesse J. Savage, Mario Duran-Prado, Rachel D. Mullen, Zachary P. Neeb, Urs Eiholzer, Volker Hesse, Nadine G. Haddad, Heike M. Stobbe, Werner F. Blum, Johannes F. W. Weigel, and Simon J. Rhodes. Three novel missense mutations within the lhx4 gene are associated with variable pituitary hormone deficiencies. The Journal of Clinical Endocrinology &amp; Metabolism, 93(3):1062–1071, March 2008. URL: http://dx.doi.org/10.1210/jc.2007-1525, doi:10.1210/jc.2007-1525. This article has 86 citations.](https://doi.org/10.1210/jc.2007-1525)

[9. (Meier1999Characterization) Bradley C. Meier, Jeffrey R. Price, Gretchen E. Parker, JeAnne L. Bridwell, and Simon J. Rhodes. Characterization of the porcine lhx3/lim-3/p-lim lim homeodomain transcription factor. Molecular and Cellular Endocrinology, 147(1–2):65–74, January 1999. URL: http://dx.doi.org/10.1016/s0303-7207(98)00213-5, doi:10.1016/s0303-7207(98)00213-5. This article has 32 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0303-7207(98)00213-5)

[10. (Hemwong2020A) Nalinee Hemwong, Chureerat Phokaew, Chalurmpon Srichomthong, Siraprapa Tongkobpetch, Khomsak Srilanchakon, Vichit Supornsilchai, Kanya Suphapeetiporn, Thantrira Porntaveetus, and Vorasuk Shotelersuk. A patient with combined pituitary hormone deficiency and osteogenesis imperfecta associated with mutations in lhx4 and col1a2. Journal of Advanced Research, 21:121–127, January 2020. URL: http://dx.doi.org/10.1016/j.jare.2019.10.006, doi:10.1016/j.jare.2019.10.006. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jare.2019.10.006)